Skip to main content
OpenTrials
Completed

NCT Number: NCT06022562

Effects of Gender-affirming Hormone Therapy on Transgender People

This prospective cohort study aims to assess the impact of gender-affirming hormone therapy (GAHT) on transgender individuals' physical, psychological, social, and quality of life aspects. Based on gender minority stress theory, the research recruits 150 individuals each of those starting GAHT and those not yet undergoing it. Data collection involves questionnaires and physiological measurements. Statistical analyses will explore correlations and group differences. Findings can guide transgender individuals considering hormone therapy and enhance care guidelines to improve their overall well-being.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gender Dysphoria Behavior Behavioral Symptoms Depression Mental Disorders Sexual Dysfunctions, Psychological

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Taiwan University, College of Medicine, School of Nursing

Taipei, Taiwan

About this study

The willingness and proportion of transgender persons diagnosed with gender dysphoria to receive gender-affirming hormone therapy (GAHT) is relatively high, so as to conform to their internal gender identity. However, there are limited studies on the prospectively observation of the influences and effectiveness of GAHT on physical, psychological, social and quality of life of transgender people. This study is a cross-sectional research prospective cohort study design, and the research framework is developed based on gender minority stress theory. It is expected to recruit a group of 150 transgender people, including trans male, trans female, and non-binary person, who have just started using GAHT, and a group of 150 who has not yet received GAHT. The data collection time is about 40-50 minutes each time. The questionnaires will be applied to collect basic demographic information, basic hormonal information, body changes, body image, sexual wellbeing, sexual risk, depression, social support, and quality of life. The instruments will be applied to measure participants' physiological parameters, including weight, body fat, and muscle mass, hand grip strength, and blood pressure. In the statistical part, correlation and regression will be used to analyze the degree of correlation between variables, and multivariate analysis of covariance will be used to detect whether there was a significant difference between the variables of the two groups. A well understanding of the experiences and reactions of transgender people receiving hormone therapy can provide a reference for transgender people before deciding to accept hormone therapy, and can be used as an important reference for formulating care guidelines for gender-affirming hormone therapy to improve the care quality for the gender minority population.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • transgender

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. Transgender Congruence Scale

    Time frame: 1 year

    Participants rated this 15 items scale on a 5-point Likert-type scale (i.e., 1 = strongly disagree, 2 = somewhat disagree, 3 = neither agree nor disagree, 4 = somewhat agree, 5 = strongly agree). Four of the 15 items were designed to be reverse-scored. Item responses were averaged, with higher scores indicating a higher level of congruence. So the maximum and minimum values of this scale are 75 and 15.

  2. Gender Affirming Hormone Treatment Physical Symptoms Assessment Scale

    Time frame: 1 year

    Participants rated this 17 items scale on a 4-point Likert-type scale. With higher scores indicates a higher level.

  3. Sexual Risk Survey (SRS) Items

    Time frame: 1 year

    Participants rated this 23 items. This questionnaire inquires about the frequency of subjects' experiences with each sexual risk. A higher frequency indicates a greater level of risk.

  4. Short Sexual Well Being Scale

    Time frame: 1 year

    Participants rated this 5 items scale on a 7-point Likert-type scale. With higher scores indicates a higher level.

  5. Transgender individual Quality of Life

    Time frame: 1 year

    Participants rated this 23 items scale on a 4-point Likert-type scale. With higher scores indicates a higher level.

  6. Beck Depression Inventory-II

    Time frame: 1 year

    The BDI-II, or Beck Depression Inventory-II, is a widely used self-report assessment tool for measuring the severity of depression. It consists of 21 multiple-choice questions or items. Of these 21 items, 13 are scored in the direction of increasing depression severity, while the remaining 8 are reverse-scored to assess positive attributes.

    The possible score range on the BDI-II is from 0 to 63, with higher scores indicating more severe depressive symptoms.

  7. Multidimensional Perceived Social Support Scale

    Time frame: 1 year

    The Multidimensional Perceived Social Support Scale (MPSSS) is a self-report questionnaire designed to assess an individual's perception of the level of social support they receive. It measures support from various sources, such as family, friends, and significant others, and evaluates different dimensions of support, including emotional, instrumental, and informational support. Participants rated this 13 items scale on a 4-point Likert-type scale with 4 different social related group. With higher scores indicates a higher level.

Sponsors and collaborators

Lead sponsor

National Taiwan University

Other

Registry information

Official study title

Effects of Gender-affirming Hormone Therapy on the Psychosocial and Quality of Life of Transgender People: A Prospective Cohort Study

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 5, 2023
Registry last updated
Aug 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.